Surgery in Treating Patients With Neuroblastoma

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Surgery in Treating Patients With Neuroblastoma
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00003122
  • Trial

    -
    Health Condition(s) or Problem Neuroblastoma
    Lay Summary RATIONALE: Surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase II trial is studying how well surgery works in treating patients with neuroblastoma. (from ClinicalTrials.gov)
    Who can enter the trial DISEASE CHARACTERISTICS: - Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage IIA and IIB neuroblastoma without amplification of the N-myc oncogene - Study: Histologically proven neuroblastoma - Stage I - Stage II with amplified N-myc - Stage II without evaluation of N-myc - Stage II with symptomatic spinal cord compression - Stage III - No metastases diagnosed within 1 month of study PATIENT CHARACTERISTICS: Age: - 20 and under Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy - No adjuvant chemotherapy planned Endocrine therapy: - Prior use of steroids allowed Radiotherapy: - Not specified Surgery: - Not specified
    Who cannot enter the trial DISEASE CHARACTERISTICS: - Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage IIA and IIB neuroblastoma without amplification of the N-myc oncogene - Study: Histologically proven neuroblastoma - Stage I - Stage II with amplified N-myc - Stage II without evaluation of N-myc - Stage II with symptomatic spinal cord compression - Stage III - No metastases diagnosed within 1 month of study PATIENT CHARACTERISTICS: Age: - 20 and under Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy - No adjuvant chemotherapy planned Endocrine therapy: - Prior use of steroids allowed Radiotherapy: - Not specified Surgery: - Not specified
    What will happen Procedure; surgical procedure
    Primary aim Safety and efficacy; Predictive factors of relapse and survival
    Secondary Aim Sorry, not currently available
    Participant Information Sheet Sorry, not currently available
    Website http://cancer.gov/clinicaltrials/SIOP-95-1
    Recruitment Status Recruiting
    Nation England, Northern Ireland, Scotland, Wales
    Location Bristol, Cambridge, Leicester, Liverpool, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford, Sheffield, Southampton, Sutton, Belfast, Aberdeen, Edinburgh, Glasgow, Penarth
  • Contact

    -
    Contact for Public Queries Jean Marie Michon, MD Study Chair Institut Curie
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.